The CEO of "Abdi İbrahim" company expressed interest in the Tashkent Pharma Park cluster.

Examining the innovative scientific-production pharmaceutical cluster, Nezih Barut emphasized the uniqueness of this project as a consolidator of regulatory bodies, research centers, laboratories, institutes, and manufacturing facilities in Central Asia. At the end of the visit, parties agreed to engage in discussions to enhance collaboration further.

For information:
"Abdi İbrahim," a leading player in the Turkish pharmaceutical market with over a century of experience, produces more than 100 types of drugs used in the treatment and prevention of various diseases such as diabetes, tuberculosis, HIV, cardiological, psychoneurological, gastroenterological, gynecological, endocrine, and others.